Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2020; 17(15):2248-2256. doi:10.7150/ijms.47405 This issue Cite

Research Paper

Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways

Hao Lin1*, Tingrui Wu1*, Lijiao Peng2*, Wenmei Su2, Yingxin Wang1, Xiao Li1, Qianzheng Liu1, Chanli Zhong3, Jing Huang2✉, Bo Wei1✉

1. Department of Orthopedics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524001, China.
2. Oncology Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524001, China.
3. Institute of Laboratory Medicine, Guangdong Medical University, Dongguan, Guangdong, 523808, China.
*These authors contribute equally to this study.

✉ Corresponding authors: Jing Huang, Ph.D., Oncology Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China, E-mail: hj841023com; and Bo Wei, Ph.D., Department of Orthopedics, Affiliated Hospital of Guangd More

Citation:
Lin H, Wu T, Peng L, Su W, Wang Y, Li X, Liu Q, Zhong C, Huang J, Wei B. Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways. Int J Med Sci 2020; 17(15):2248-2256. doi:10.7150/ijms.47405. https://www.medsci.org/v17p2248.htm
Other styles

File import instruction

Abstract

Osteosarcoma (OS) is the most common type of malignant bone tumor that affects children and adolescents. Still, the cellular and molecular mechanisms driving the development of this disease remain poorly understood. In this study, numerous dysregulated lncRNAs were identified by RNA-seq. As a result, we were able to find a novel lncRNA Lnc-MAP6-1:3 which is highly expressed in osteosarcoma. Using a set of approaches including gene knockdown, RT-PCR, oncogenic function assay and western blotting, we observed that knockdown of Lnc-MAP6-1:3 expression suppressed cell proliferation and colony formation, and promoted apoptosis in vitro. For the first time, we have identified that Lnc-MAP6-1:3 potentially influence the malignant behavior of osteosarcoma via Bax/Bcl-2 and Wnt/β-catenin signaling pathways. Henceforth, Lnc-MAP6-1:3 may provide a new molecular route of research and therapeutic applications for the diagnosis and treatment of osteosarcoma.

Keywords: Lnc-MAP6-1:3, Osteosarcoma, Oncogenic lncRNA, Bax/Bcl-2, Wnt/β-catenin

Citation styles

APA
Lin, H., Wu, T., Peng, L., Su, W., Wang, Y., Li, X., Liu, Q., Zhong, C., Huang, J., Wei, B. (2020). Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways. International Journal of Medical Sciences, 17(15), 2248-2256. https://doi.org/10.7150/ijms.47405.

ACS
Lin, H.; Wu, T.; Peng, L.; Su, W.; Wang, Y.; Li, X.; Liu, Q.; Zhong, C.; Huang, J.; Wei, B. Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways. Int. J. Med. Sci. 2020, 17 (15), 2248-2256. DOI: 10.7150/ijms.47405.

NLM
Lin H, Wu T, Peng L, Su W, Wang Y, Li X, Liu Q, Zhong C, Huang J, Wei B. Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways. Int J Med Sci 2020; 17(15):2248-2256. doi:10.7150/ijms.47405. https://www.medsci.org/v17p2248.htm

CSE
Lin H, Wu T, Peng L, Su W, Wang Y, Li X, Liu Q, Zhong C, Huang J, Wei B. 2020. Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways. Int J Med Sci. 17(15):2248-2256.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use